Holen Sie sich die Stockscreener-App
7.27
2.02%
-0.15
Vorhandelsmarkt:
7.80
0.53
+7.29%
Eupraxia Pharmaceuticals Inc Aktie (EPRX) Neueste Nachrichten
Eupraxia Pharmaceuticals Posts Strong Histologic Gains in Mid-Stage EoE Trial for EP-104GI - TipRanks
Eupraxia (EPRX) shows >90% EoE tissue score gains at top RESOLVE dose - Stock Titan
Eupraxia reports endoscopy score data from EoE trial By Investing.com - Investing.com Australia
Eupraxia Pharmaceuticals Reports EREFS Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week - Investing News Network
Eupraxia Pharmaceuticals Highlights Strong EP-104GI EoE Data From RESOLVE Trial at DDW - TipRanks
Why 20 shots matter: Eupraxia links fuller dosing to lower EoE scope scores - Stock Titan
Eupraxia Pharmaceuticals Price Target Maintained With a $11.00/Share by HC Wainwright & Co. - Moomoo
Eupraxia Pharmaceuticals: Tambiah to Succeed Mark Kowalski - Moomoo
Eupraxia Pharmaceuticals Names New Chief Medical Officer to Steer Late-Stage Pipeline - TipRanks
Eupraxia Pharmaceuticals Appoints Dr. Jeymi Tambiah as Chief Medical Officer - Investing News Network
Eupraxia appoints Dr. Jeymi Tambiah as chief medical officer - Investing.com UK
Eupraxia appoints Dr. Jeymi Tambiah as chief medical officer By Investing.com - Investing.com Nigeria
Surgeon-scientist Jeymi Tambiah joins Eupraxia as CMO - Stock Titan
Osteoarthritis Market to Evolve Rapidly Over the Next Decade by 2034, DelveInsight Observe | Merck KGaA, Peptinov, LG Chem, Akan Bioscience, BioTissue,Inc., Eupraxia Pharmaceuticals Inc., OliPass Corp - Barchart.com
A Quick Look at Today's Ratings for Eupraxia Pharmaceuticals(EPRX.US), With a Forecast Between $11 to $16 - Moomoo
Eupraxia Pharmaceuticals (EPRX) to Release Quarterly Earnings on Wednesday - MarketBeat
Eupraxia Pharmaceuticals Shares Drop After $70 Million Offering Pricing - MSN
Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Eupraxia Pharmaceuticals to Present at Digestive Disease Week Annual Meeting - Sahm
EPRX Eupraxia Pharmaceuticals posts wider than expected Q4 2025 loss on zero revenue, shares dip nearly 1 percent. - Cổng thông tin điện tử Tỉnh Sơn La
Eupraxia Pharmaceuticals Inc. - Mena FN
Stocks in play: Eupraxia Pharmaceuticals Inc. - Barchart.com
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Receives Buy Rating from HC Wainwright - MarketBeat
Eupraxia Pharmaceuticals to Showcase EP-104GI Data at Digestive Disease Week 2026 - TipRanks
EP-104GI esophagitis data and DDW investor event for Eupraxia (TSX: EPRX) - Stock Titan
Eupraxia Pharmaceuticals Reports Positive Nine-Month Tissue Health and Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis - Investing News Network
Eupraxia Posts Strong 36-Week EoE Data From Highest-Dose Cohort in RESOLVE Trial - TipRanks
Experimental esophagus treatment kept symptoms in remission for 36 weeks - Stock Titan
Canadian Investment Regulatory Organization Trading Halt – EPRX.WT.A - Weekly Voice
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Raised to "Sell" at Wall Street Zen - MarketBeat
Eupraxia Pharmaceuticals (EPRX) Stock: Trendline Structure (Selling Pressure) 2026-04-16Expert Entry Points - Cổng thông tin điện tử tỉnh Lào Cai
Eupraxia Pharmaceuticals to Highlight Drug-Delivery Pipeline at April Investor Conferences - TipRanks
Eupraxia (EPRX) to showcase Diffusphere pipeline at April investor events - Stock Titan
Eupraxia Pharmaceuticals (EPRX) schedules June 18, 2026 annual meeting - Stock Titan
EPRX Price Today: Eupraxia Pharmaceuticals Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Eosinophilic Esophagitis Market in the US to Grow at 13.2% CAGR During the Forecast Period (2026–2036) Owing to the Emergence of Drug Classes Such as TSLP Inhibitors, Glucocorticoid Receptor Agonists, and Immunomodulators | DelveInsight - GlobeNewswire Inc.
Eupraxia Pharmaceuticals to Present at Upcoming Investor Conferences - Investing News Network
Eupraxia's April 21 Toronto conference presentation will be webcast - Stock Titan
Is Eupraxia Pharmaceuticals (EPRX) Stock tied to economic cycles | Price at $7.12, Up 3.72%Top Analyst Picks - Newser
New Highs: Can VLYPP weather a recessionTrade Performance Summary & AI Driven Price Forecasts - baoquankhu1.vn
Top iBio (IBIO) Competitors 2026 - MarketBeat
Whats the beta of Eupraxia Pharmaceuticals Inc stock2026 Top Gainers & Technical Pattern Recognition Alerts - baoquankhu1.vn
Eupraxia Pharmaceuticals Inc. (EPRX) - Minichart
Institution Moves: What are Eupraxia Pharmaceuticals Incs recent SEC filings showing2026 EndofYear Setup & Free Technical Confirmation Trade Alerts - baoquankhu1.vn
How does Eupraxia Pharmaceuticals (EPRX) Stock compare to competitors | Price at $6.77, Down 4.65%Profit Surge - Newser
Can Eupraxia Pharmaceuticals (EPRX) Stock Go Higher | Price at $7.10, Down 0.98%Shared Trade Ideas - Newser
EPRX SEC FilingsEupraxia Pharmac 10-K, 10-Q, 8-K Forms - Stock Titan
New strong sell stocks for April 2nd - MSN
New Strong Sell Stocks for April 2nd - Yahoo Finance
ETFs Investing in Eupraxia Pharmaceuticals, Inc. Stocks - TradingView
Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
0.14%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):